Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 9 of 43

News about companies that support development of orally inhaled and nasal drug products (OINDPs), including regulatory approvals, new partnerships, new products and services, and results of clinical studies. 8 OctOber 2026 Inhalation will offer a full range of spray- dried dispersion capacity to sup- port customers across both clinical and commercial programs. rough its integrated end-to-end offering, Lonza will also support develop- ment and manufacturing of small molecules and other modalities, including biologics and mRNA. e new facility will be equipped with two state-of-the-art PSD-4 spray-drying units, allowing for future capacity expansions. Addi- tional upgrades to the Bend site will include supporting infrastruc- ture for solvent handling and stor- age. e project will also integrate energy-efficient utility and pro- cess systems and enhanced emis- sion control technologies to reduce overall facility energy demand. e new facility is expected to be com- pleted in 2029 and will initially cre- ate more than 80 new jobs. "e investment in the Bend site reflects our conviction that the United States will remain a leading source of pharmaceutical innovation and a key market for Lonza," said Wolf- gang Wienand, Chief Executive Officer, Lonza. Aurobindo launches generic version of Advair Diskus ® in US EAST WINDSOR, NEW JERSEY, UNITED STATES—Aurobindo Pharma USA subsidiary Lannett Company announced its United States launch of the generic equiv- alent of Advair Diskus ® (flut- icasone propionate/salmeterol inhalation powder), a product of GSK (London, United Kingdom), in 100/50 mcg and 250/50 mcg strengths. A company news release stated the product is the first from their inhalation pipeline to be com- mercialized in the US and noted that Advair Diskus is indicated for the treatment of asthma and chronic obstructive pulmonary dis- ease (COPD). In addition, Aurob- indo announced final approval from the United States Food and Drug Administration (FDA) to manu- facture and market Beclometha- sone Dipropionate HFA Inhalation Bespak and Upperton to collaborate on nasal drug product development HOLMES CHAPEL, UNITED K I N G D O M — B e s p a k a n d Upperton have entered into a stra- tegic collaboration to provide an integrated pathway for the devel- opment and manufacture of nasal drug-device combination products using Bespak's expanded propri- etary device portfolio. According to a Bespak news release, the collabo- ration extends Bespak's nasal capa- bilities by combining its capabilities in nasal device design, development engineering, industrialization and commercial supply with Upperton's formulation development, analytical and clinical manufacturing capabili- ties. Together, the companies aim to provide a more seamless route from early opportunity assessment and formulation- device development through clinical supply, scale-up and commercial manufacture. e new combined offering will support liquid, soft mist and dry powder for- mulations across Bespak's single and multi-dose nasal device portfolio. "Nasal drug delivery is an exciting and rapidly evolving area, partic- ularly as developers explore new opportunities for systemic deliv- ery of CNS therapies and innova- tive nose-to-brain applications," said Chris Hirst, CEO, Bespak. "Successful development requires formulation, device and manufac- turing strategies to work together from the outset," Nikki Whitfield, CEO, Upperton, noted. "Bring- ing our specialists together around each program will help customers make critical development decisions earlier and provide a clearer path- way from development and clinical supply towards commercialization. Lonza to add commercial spray-drying facility in Bend, Oregon BASEL, SWITZERLAND—Lonza announced it will construct a new, large-scale, commercial PSD-4 spray-drying facility in Bend, Ore- gon, United States. e company INDUSTRY NEWS Copley Scientific: Two launches to advance connected workflows in inhaler testing NOTTINGHAM, UNITED KINGDOM—Copley Scientific has introduced Inhalytix ® + v2.0 and the Critical Flow Controller TPK 200iX for connected, digi- tized inhaler testing, both designed to address challenges in fragmented workflows, manual data handling, disconnected systems and informa- tion silos. e company describes Inhalytix ® + as a digital hub for inhaler testing data management that can bring methods, users, equipment information, inhaler testing data, reports and audit trails together within a controlled digital workflow. Inhalytix ® + v2.0 can strengthen equipment con- nectivity and expand the tools available for managing, analyz- ing and reporting inhaler testing data, helping laboratories work with greater consistency, visibility and traceability. e Critical Flow Controller TPK 200iX builds on the company's established TPK 100i and can combine critical flow control for Delivered Dose Uni- formity (DDU) and Aerodynamic Particle Size Distribution (APSD) assessments with a new guided user experience, extended testing capa- bility and enhanced digital work- flow control. "e inhaler testing laboratory is changing," said Paul Martin, Head of Business Devel- opment, Copley Scientific. "Cus- tomers need greater confidence in their results and the workflows delivering them. Stronger method control, fewer sources of variability and rigorous data management are becoming essential to progress effi- ciently and demonstrate the robust consistency and integrity that reg- ulators are [seeking]." continued on page 38

Articles in this issue

view archives of Inhalation - INH1026